Company intelligence / Profile preview

Vcanbio Cell & Gene Engineering Corp., Ltd.

Tianjin, Tianjin, Chinavcanbio.com ↗

Ownership: Private
Employees: ~2014
Development stage: Commercial

Overview

The company has multiple programs in clinical development, with VUM-02 in Phase 2 for Steroid Refractory Graft Versus Host Disease, YW-CARCD19-T in Phase 1 for B-Cell Leukemia, and VUM-03 with IND Approval for Perianal fistula due to Crohn's disease.

Therapeutic areas: OncologyImmunologyGastroenterology
Modalities: Stem cell therapyCAR-TMonoclonal antibodyMesenchymal stem cell therapyCytokine-induced Killer Cell (CIK)
Industry: Biotech

Drug pipeline

2 assets

umbilical cord-derived allogeneic mesenchymal stem cells

1 more asset in the full pipeline.

Request access →

Partnerships

Lanzhou University

Beyond the preview

Go deeper on Vcanbio Cell & Gene Engineering Corp., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vcanbio Cell & Gene Engineering Corp., Ltd..

Explore the full profile